Neuroblastoma Clinical Trials

524 clinical trials for Neuroblastoma across international registries, including 92 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) — RECRUITING · PHASE1
• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma — RECRUITING · PHASE3
• Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas — RECRUITING · PHASE1
• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma — RECRUITING · PHASE2
• A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma — RECRUITING · PHASE2
• SPEARHEAD-3 Pediatric Study — RECRUITING · PHASE1
• Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies — RECRUITING
• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms — RECRUITING
• A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma — RECRUITING · PHASE2
• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) — RECRUITING · PHASE1
• N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma — RECRUITING · PHASE2
• NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial — RECRUITING · PHASE2
• Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma — RECRUITING · PHASE1
• Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation — RECRUITING · PHASE1
• Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma — RECRUITING · PHASE1
• Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors — RECRUITING · PHASE1
• PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy — RECRUITING · PHASE1
• Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors — RECRUITING · PHASE1
• 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma — RECRUITING · PHASE1
• Familial Investigations of Childhood Cancer Predisposition — RECRUITING
• Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma — RECRUITING · PHASE2
• Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children — RECRUITING · PHASE2
• Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma — RECRUITING · PHASE2
• 68Ga-DOTATATE Neuroblastoma Imaging Pilot — RECRUITING · PHASE2
• B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) — RECRUITING · PHASE1
• Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. — RECRUITING · NA
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors — RECRUITING · PHASE1
• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors — RECRUITING · PHASE1
• Phase II Study of Proton Radiation Therapy for Neuroblastoma — RECRUITING · NA
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors — RECRUITING · PHASE1
• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy — RECRUITING · PHASE2
• Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma — RECRUITING · PHASE2
• Agnostic Therapy in Rare Solid Tumors — RECRUITING · PHASE2
• Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies — RECRUITING · PHASE1
• A PHASE 2/3 STUDY TO CHARACTERIZE AND EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF HU 14.18K322A TREATMENT GIVEN IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NEUROBLASTOMA — RECRUITING · PHASE2
• Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma — RECRUITING
• Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma — RECRUITING · PHASE1
• Neuroblastoma Biology Study — RECRUITING
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) — RECRUITING · PHASE3
• An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma — RECRUITING · PHASE1
• Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma — RECRUITING · NA
• 18F-DOPA II - PET Imaging Optimization — RECRUITING · PHASE3
• Engineering Immune Organoids to Study Pediatric Cancer — RECRUITING · NA
• Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. — RECRUITING · PHASE1
• Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma — RECRUITING · PHASE3
• Biomarkers of Resiliency In Childhood Cancer Surgery — RECRUITING
• Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma — RECRUITING · PHASE1
• Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma — RECRUITING · NA
• DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers — RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations — RECRUITING · PHASE2

Refine this search